Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recent research has indicated that physical activities incorporating moderate-intensity exercise can be safely performed during treatment and substantially reduces treatment-related side effects, such as fatigue, sleep disturbances, cognitive impairment, and nausea. However, little is known about physical activity levels prior to treatment and whether providing an exercise intervention pre-treatment may improve functional capacity during treatment.
The purpose of this study is to
Measure physical activity levels and functional capacity in men newly diagnosed with prostate cancer prior to treatment and
Explore whether a 2-week physical activity intervention is feasible during the pre-treatment timeframe:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| subjects with prostate cancer | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exrecise intervention | Behavioral | Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in 6 minute walk test | Distance walked in 6 minutes | baseline, 2 weeks post intervention |
| Change in balance test | Ability to balance | baseline, 2 weeks post intervention |
| Change in time up to go test | Time to get up from chair, walk 30 meters and return to sit in chair | baseline, 2 weeks post intervention |
| Change in Godin Leisure Time Score | physical activity score | baseline, 2 weeks post intervention |
| Change in rate of perceived exertion | physical exertion score | baseline, 2 weeks post intervention |
| Change in metabolic equivalent | metabolic activity score | baseline, 2 weeks post intervention |
| Change in distress score | distress score | baseline, 2 weeks post intervention |
| Change in self-efficacy score | self-efficacy score | baseline, 2 weeks post intervention |
| Change in symptom inventory score |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Deborah Allen | Duke University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke Raleigh Cancer Center | Raleigh | North Carolina | 27606 | United States |
No plan to share feasibility study data
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
description of symptoms |
| baseline, 2 weeks post intervention |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D001519 | Behavior |